Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting EGFR degradation by autophagosome degraders.

European journal of medicinal chemistry - 15 Apr 2024

Zhu ZhongFeng, Li Jiaying, Shen Shujun, Al-Furas Hawaa, Li Shengrong, Tong Yichen, Li Yi, Zeng Yucheng, Feng Qianyi, Chen Kaiyue, Ma Nan, Zhou Fengtao, Zhang Zhang, Li Zhengqiu, Pang Jiyan, Ding Ke, Xu Fang

Abstract excerpt

Several generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been developed for the treatment of non-small cell lung cancer (NSCLC) in clinic. However, emerging drug resistance mediated by new EGFR mutations or activations by pass, leads to malignant progression of NSCLC. Proteolysis targeting chimeras (PROTACs) have been utilized to overcome the drug resistance acquired by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagosomes
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Cell Proliferation

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 38564826
DOI: 10.1016/j.ejmech.2024.116345

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting EGFR degradation by autophagosome degraders.PMID 38564826Read ↗

Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.Semantic proximity Read ↗

Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems.Semantic proximity Read ↗

Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.Semantic proximity Read ↗

Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.Semantic proximity Read ↗

Discovery of highly potent and selective CRBN-recruiting EGFRL858R/T790M degraders in vivo.Semantic proximity Read ↗

Proteolysis targeting chimeras in non-small cell lung cancer.Semantic proximity Read ↗

Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.Semantic proximity Read ↗

Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations.Semantic proximity Read ↗

[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy].Semantic proximity Read ↗

Design and synthesis of selective degraders of EGFRL858R/T790M mutant.Semantic proximity Read ↗

Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung CancerSemantic proximity Read ↗

Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.